Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

(Reuters) - Eli ... Lilly's and Danish rival Novo Nordisk's diabetes and weight-loss drugs has been extraordinary. The new launches present a big market opportunity as they are some of the most ...

(Reuters) - Eli Lilly plans ... Global demand for Lilly's and Danish rival Novo Nordisk's diabetes and weight-loss drugs has been extraordinary. The new launches present a big market opportunity as ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Like many pharma stocks, Eli Lilly ... These drugs all have produced impressive results in clinical trials and in the real world, and that has kept them flying off pharmacy shelves. On top ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...